← Back to headlines
PharmAla Biotech Secures $100 Million US Licensing Deal for MDMA Therapy
PharmAla Biotech has signed a term sheet for a significant $100 million U.S. licensing deal. The agreement pertains to its ALA-002 MDMA therapy, marking a major development for the company.
20 May, 15:12 — 20 May, 15:12
Sources
Showing 1 of 1 sources
Related Stories
Bitcoin Drops Below $78,000 Following Fed Chair’s Hawkish Jackson Hole Remarks
25m ago
College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales
1h ago
Fed Chair Warsh Warns of Potential Rate Hikes Amid Stubborn Inflation
2h ago
Temasek Backs Singapore Airlines’ Strategic Investment in Air India
2h ago